Design Synthesis and Structural Elucidation of Novel Impurities in Selected Active Pharmaceutical Ingredients of Bulk Drugs Baricitinib Venetoclax and Erlotinib
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The discovery and synthesis of impurities in Active Pharmaceutical Ingredient (API) molecules
newlineare critical for assuring drug safety, quality, and regulatory compliance. Impurities might come
newlinefrom the initial ingredients, intermediates, side reactions, degradation processes, or residual
newlinesolvents. Their presence, even in small amounts, can have an impact on the efficacy and safety
newlineof the finished drug product. Regulatory requirements, such as ICH Q3A and Q3B, mandate
newlinethe detection and qualification of contaminants that exceed particular criteria, emphasizing the
newlineimportance of rigorous analytical and synthetic techniques. The main objective of this thesis is
newlineidentification and synthesis of API molecules available in the current drug market. We mainly
newlinefocused on Baricitinib, Venetoclax and Erlotinib. Baricitinib Lactone (BCL), Baricitinib dimer
newline(BCD), Baricitinib hydroxy methyl (BHM) impurities were identified as synthetic impurities
newlineof Baricitinib. Oxidative degradation studies of Venetoclax lead to the identification of
newlineVenetoclax N-Oxide (VNO) Venetoclax hydroxyl amine (VHA) impurities. Similarly, 6,7-O-
newlineDidesmethyl erlotinib (DP-1), Erlotinib dihydroxy impurity (DP-2), 7-O-desmethyl erlotinib
newline(DP-3), and 6-O-desmethyl erlotinib (DP-4) were identified as the acidic degradation products
newlineof Erlotinib.
newlineChapter-1 Introduction
newlineChapter-2 4.1 Isolation, Synthesis and Characterization of Novel Synthetic Impurities of
newlineBaricitinib
newlineChapter-3 2. Synthesis and Characterization of unique oxidative impurities of Venetoclax
newlineincluding Meisenheimer rearrangement product
newlineChapter-4 3. Identification and synthesis of unprecedented acid-induced degradation
newlineproducts of Erlotinib
newlineChapter-5 Summary and Future Works.
newline
newline